Provention Bio, Inc. (PRVB)
(Delayed Data from NSDQ)
$3.98 USD
+0.18 (4.74%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[PRVB]
Reports for Purchase
Showing records 21 - 40 ( 48 total )
Industry: Medical - Biomedical and Genetics
PRV-3279 Preclinical Data Released; Cash Replenished; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Teplizumab Application Accepted for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
3Q20 Financials; Teplizumab Submission Being Reviewed. Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Rolling Biologics License Application Submission Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Celiac Disease Foundation Partnership on PRV-015 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Regulatory Progress; Type 1 Diabetes Screening Campaign; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Phase 2b PROACTIVE Celiac Disease Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Teplizumab Continues to Advance; 2Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Equity Financing Provides Runway Through Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Additional Long-Term Clinical Data Bolsters PRV-031 Case; Raising PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Teplizumab Continues Advance Toward FDA Submission; 1Q20 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Rolling Biologics License Application Started; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PROTECT Study Randomization Paused; 2019 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PRV-6527 Licensing Option Waived; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Teplizumab Regulatory Filing Clearance Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
3Q19 Financial Results Reported; FDA Meeting Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PRIME Designation for Teplizumab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PRINCE Study Fails, Narrowing Focus to Teplizumab; Strong Financial Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Teplizumab Filing Timeline Clarity Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R